BioMarin Trial Halt Raises Another Safety Flag On AAV Gene Therapy

US FDA Safety Probe Is Ongoing

 
• By Andrew McConaghie
  
Brisbane, CA, USA - Mar 1, 2020: The BioMarin logo seen at American biotechnology company BioMarin Pharmaceutical Inc.'s office in Brisbane, California.
BioMarin is the latest company to be hit by AAV gene therapy safety doubts, as the FDA takes a cautious approach to the burgeoning field.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Alimentary/Metabolic

More from Therapeutic Category